UPDATE: Crinetics Pharmaceuticals (CRNX) - The Antitrust Gate Opens

Eleven days ago I closed the Q2 update with the line that everything from here is “proxy mechanics and a 1.5% spread.” Today’s 8-K knocked out the mechanics. The Hart-Scott-Rodino waiting period expired at 12:45 p.m. ET on August 12, 2026. As of August 13, the required approvals in Austria, Germany, and Australia have been received — with one residual Australian waiting period scheduled to lapse August 27, 2026 at 9:59 a.m. ET. The Crinetics special meeting is set for August 28, 2026, and management now expects the merger to close in early September 2026.

The stock sits at $84.70, up +1.1% from the $83.76 close on August 3, against $85.00 in cash consideration. The spread is now $0.30, or 0.35%.

• HSR clearance, no second request. The waiting period simply expired on August 12 rather than being extended. The implication: the FTC did not open an in-depth review. This is the outcome I handicapped in the July 6 update — “the overlap between Vertex’s portfolio (CF, SCD, acute pain, kidney, T1D pipeline) and Crinetics’ endocrinology franchise is minimal. No obvious substantive theory of harm.” Regulators agreed. Antitrust risk on this deal is now essentially a calendar item, not a question.

• Foreign clearances in hand: Austria, Germany, Australia. All three received as of August 13, with only an Australian statutory waiting period still running to August 27. Why it matters: Germany and Austria were the two markets Crinetics chose for the initial European PALSONIFY launch. The competition authorities that scrutinize those markets waved it through in roughly five weeks.

• Special meeting: August 28, 2026. Definitive proxy was filed and mailed July 31. The vote is a simple majority of outstanding shares, with two fairness opinions (Leerink, J.P. Morgan) already delivered and Farallon’s 8,989,098 shares (8.5%) sitting undiminished through the event window. The implication: an anchor holder that rode $42 → $85 and did not sell into the spread is voting for the cash.

• Close guided to early September 2026. That is inside the original “expected Q3 2026” framing and roughly four months ahead of the January 6, 2027 outside date. The $350.5M termination fee — ~3.5% of a ~$10.0B equity value — remains the only remaining door for an interloper, and it has stayed shut for six weeks.

Reading the timeline is the whole exercise here. Between the August 27 Australian lapse and the August 28 vote, there is no meaningful gap left for something to go wrong. Everything sequences: waiting period ends, shareholders vote the next morning, funds move in early September.

Share

What actually changed in the risk profile. In the July 6 post I named three residual risks — interloper (positive tail), antitrust (low but real), vote (very low). Antitrust was the only one with genuine timing uncertainty attached, because the current regulatory posture has slow-walked deals with far thinner theories of harm than this one. That risk is now off the board. What remains is a shareholder vote with a fairness-opinion-backed unanimous board recommendation and an 8.5% holder already on side.

The spread tells you the market agrees. At $0.30 on $85.00, the market is pricing close probability at something north of 98% over a roughly three-week window. That is not a return; that is a money-market rate with headline risk attached. The asymmetry I flagged on August 3 — 1.5% of upside against a realistic 25–35% air pocket on a termination headline — has gotten worse in ratio terms even as the probability of the bad outcome fell. Less upside, same tail.

And the interloper case is now effectively dead. Six weeks post-announcement, past HSR, past three foreign regulators, eight business days from the vote. A second bidder from the short list I named — Novartis, Lilly, Novo, Amgen, Ipsen, Recordati — would have to appear inside a two-week window and eat the break fee against a board that has already delivered its recommendation. The $0.30 spread says nobody is underwriting that.

The science story ends here as a public equity. PALSONIFY at $24.0M in Q2 off 385 unique prescribers with >70% reimbursed, atumelnant’s -67% mean A4 reduction and its Rare Pediatric Disease Designation, the 96-week PATHFNDR-1 OLE durability, the first n=6 ACTH-dependent Cushing’s cohort with 3 of 6 patients hitting normal urinary free cortisol at 40 mg — all of that compounding is now Vertex’s to own and report. The pipeline-in-a-pill thesis I underwrote worked; the vehicle that carried it is being retired at a fixed price on a fixed date.

Current Stance: EXIT (Maintained) — deal risk substantially resolved.

• Antitrust was the one residual condition with real timing uncertainty, and HSR expiry plus three foreign clearances retired it. What is left is a scheduled vote and a settlement date.

• The remaining return is 0.35% over ~3 weeks. For holders from the deep dive or the update series, there is no scientific or structural reason to fight the close — the cash arrives in early September.

• For anyone considering the spread here: the arithmetic has thinned to the point where this looks like a professional’s carry trade, not an investment case. Thirty cents of upside against a low-probability but violent downside is a risk profile that may warrant a hard look at sizing rather than enthusiasm.

• The one thing worth watching is the August 27 Australian waiting period lapse. If that slips, the August 28 vote still proceeds — but the close date moves, and a moving close date is the only thing that would make this spread interesting again for the wrong reasons.

The alarm I set on July 6 for the proxy has rung. The next one is August 28, and after that this ticker stops existing.

This post is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The author is a medicinal chemist, not a licensed financial advisor; the scientific analysis herein should not be interpreted as medical guidance. Biotech investing is inherently volatile — past scientific validation and early clinical data do not guarantee future late-stage clinical success or regulatory approval. Do your own due diligence.